Advertisement

An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors

  • Omalkhaire M. Alshaikh
  • Sylvia L. Asa
  • Ozgur Mete
  • Shereen EzzatEmail author
Article
First Online:

Abstract

Pituitary carcinoma is a rare disease, defined by the presence of cerebrospinal or distant metastasis of a pituitary neuroendocrine tumor (PitNET). To review our institutional experience of pituitary carcinoma, we searched the database of the UHN Endocrine Oncology Site group and the University Health Network pathology laboratory information system from 2001 to 2016. Among 1055 PitNETs from 1169 transsphenoidal resections, we identified 4 cases of pituitary carcinoma, indicating that pituitary carcinoma represents around 0.4% of PitNETs. All four patients were women. The age at initial presentation ranged from 23 to 54 years. Two patients had Cushing disease with corticotroph tumors; one was initially a densely granulated corticotroph tumor that evolved to become sparsely granulated, while the other was a Crooke cell tumor. One patient had a functioning sparsely granulated lactotroph tumor and one had a clinically silent poorly differentiated PIT1 lineage tumor. Apart from a relatively high Ki67 labeling index (≥ 10%) in three tumors, there were no cytomorphologic features at the time of initial presentation that could predict subsequent metastatic behavior. The time from diagnosis of the pituitary neuroendocrine tumor to the diagnosis of malignancy was 3 to 14 years. Therapies included somatostatin analogs, external beam radiotherapy, chemotherapies including capecitabine/temozolomide, everolimus, sunitinib, bevacizumab, and peptide receptor radionuclide therapy (PRRT). One patient died of disease 18 years after initial diagnosis, underscoring the protracted course of this ultimately fatal neuroendocrine malignancy.

Keywords

Pituitary carcinoma Pituitary neuroendocrine tumor Metastasis Ki67 
This is a preview of subscription content, log in to check access.

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Asa is a member of the Medical Advisory Boards of Leica Pathology Imaging and Ibex Medical Analytics. Dr. Ezzat has served on Medical Advisory Boards of Novartis Canada, Pfizer, Ipsen, and Esai. Drs. Alshaikh and Mete have no conflicts of interest or funding to disclose.

References

  1. 1.
    Asa SL. Tumors of the pituitary Gland. AFIP Atlas of Tumor Pathology, Series 4, Fascicle 15, Silverberg SG, editor. ARP Press, Silver Spring, MD, 2011.Google Scholar
  2. 2.
    Asa SL, Mete O. The Pituitary Gland. In: Mete O, Asa SL, editors. Endocrine Pathology. Cambridge: Cambridge University Press, 2016: 315–397.Google Scholar
  3. 3.
    Asa SL, Casar-Borota O, Chanson P, et al. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 2017; 24(4):C5-C8.PubMedCrossRefGoogle Scholar
  4. 4.
    Asa SL, Ezzat S. Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. Expert Reviews Endocrinology and Metabolism 2016; 11(2):149–162.CrossRefGoogle Scholar
  5. 5.
    Scheithauer BW, Randall RV, Laws ER, Jr., Kovacs KT, Horvath E, Whitaker MD. Prolactin cell carcinoma of the pituitary. Clinicopathological, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases. Cancer 1985; 55:598–604.PubMedCrossRefGoogle Scholar
  6. 6.
    Gabrilove JL, Anderson PJ, Halmi NS. Pituitary pro-opiomelanocortin-cell carcinoma occurring in conjunction with a glioblastoma in a patient with Cushing’s disease and subsequent Nelson’s syndrome. Clin Endocrinol (Oxf) 1986; 25:117–126.CrossRefGoogle Scholar
  7. 7.
    Kuroki M, Tanaka r, Yokoyama M, Shimbo Y, Ikuta F. Subarachnoid dissemination of a pituitary adenoma. Surg Neurol 1987; 28:71–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Luzi P, Miracco C, Lio R, et al. Endocrine inactive pituitary carcinoma metastasizing to cervical lymph nodes: a case report. Hum Pathol 1987; 18:90–92.PubMedCrossRefGoogle Scholar
  9. 9.
    Mountcastle RB, Roof BS, Mayfield RK, et al. Case Report: Pituitary adenocarcinoma in an acromegalic patient: response to bromocriptine and pituitary testing: a review of the literature on 36 cases of pituitary carcinoma. Am J Med Sci 1989; 298:109–118.PubMedCrossRefGoogle Scholar
  10. 10.
    Nawata H, Higuchi K, Ikuyama S et al. Corticotropin-releasing hormone- and adrenocorticotropin-producing pituitary carcinoma with metastases to the liver and lung in a patient with metastases to the liver and lung in a patient with Cushing’s disease. J Clin Endocrinol Metab 1990; 71:1068–1073.PubMedCrossRefGoogle Scholar
  11. 11.
    Atienza DM, Vigersky RJ, Lack EE, et al. Prolactin-producing pituitary carcinoma with pulmonary metastases. Cancer 1991; 68:1605–1610.PubMedCrossRefGoogle Scholar
  12. 12.
    Stewart PM, Carey MP, Graham CT, Wright AD, London DR. Growth hormone secreting pituitary carcinoma: a case report and literature review. Clin Endocrinol (Oxf) 1992; 37:189–195.CrossRefGoogle Scholar
  13. 13.
    Petterson T, MacFarlane IA, MacKenzie JM, Shaw MDM. Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psychiatry 1992; 55:1205–1206.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Mixson AJ, Friedman TC, Katz DA, et al. Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 1993; 76:529–533.PubMedGoogle Scholar
  15. 15.
    Cartwright DM, Miller TR, Nasr AJ. Fine-needle aspiration biopsy of pituitary carcinoma with cervical lymph node metastases: a report of two cases and review of the literature. Diagn Cytopathol 1994; 11:68–73.PubMedCrossRefGoogle Scholar
  16. 16.
    Lüdecke D, Saeger W. Carcinomas of the pituitary: definition and review of the literature. Gen Diagn Pathol 1995; 141:81–92.Google Scholar
  17. 17.
    Frost AR, Tenner S, Tenner M, Rollhauser C, Tabbara SO. ACTH-producing pituitary carcinoma presenting as the cauda equina syndrome. Arch Pathol Lab Med 1995; 119:93–96.PubMedGoogle Scholar
  18. 18.
    Beauchesne P, Trouillas J, Barral F, Brunon J. Gonadotropic pituitary carcinoma: case report. Neurosurg 1995; 37:810-815.CrossRefGoogle Scholar
  19. 19.
    Saeger W, Lüdecke DK. Pituitary carcinomas. Endocr Pathol 1996; 7:21–35.PubMedCrossRefGoogle Scholar
  20. 20.
    Garrão AF, Sobrinho LGOP, Bugalho MJ et al. ACTH-producing carcinoma of the pituitary with haematogenic metastases. European Journal of Endocrinology 1997; 137:176–180.PubMedCrossRefGoogle Scholar
  21. 21.
    Pernicone PJ, Scheithauer B, Sebo TJ, et al. Pituitary carcinoma: A clinicopathologic study of 15 cases. Cancer 1997; 79:804–812.PubMedCrossRefGoogle Scholar
  22. 22.
    Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR. Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. J Endocrinol Invest 1997; 20:230–236.PubMedCrossRefGoogle Scholar
  23. 23.
    Nose-Alberti V, Mesquita MI, Martin LC, Kayath MJ. Adrenocorticotropin-producing pituitary carcinoma with expression of c-erbB-2 and high PCNA index: A comparative study with pituitary adenomas and normal pituitary tissues. Endocr Pathol 1998; 9(1):53–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Hinton DR, Hahn JA, Weiss MH, Couldwell WT. Loss of Rb expression in an ACTH-secreting pituitary carcinoma. Cancer Lett 1998; 126(2):209–214.PubMedCrossRefGoogle Scholar
  25. 25.
    Kemink SA, Wesseling P, Pieters GF, Verhofstad AA, Hermus AR, Smals AG. Progression of a Nelson’s adenoma to pituitary carcinoma; a case report and review of the literature. J Endocrinol Invest 1999; 22:70–75.PubMedCrossRefGoogle Scholar
  26. 26.
    Zahedi A, Booth GL, Smyth HS, et al. Distinct clonal composition of primary and metastatic adrencorticotrophic hormone-producing pituitary carcinoma. Clin Endocrinol (Oxf) 2001; 55(4):549–556.CrossRefGoogle Scholar
  27. 27.
    Gaffey TA, Scheithauer BW, Lloyd RV, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 2002; 96(2):352–360.PubMedCrossRefGoogle Scholar
  28. 28.
    Lim S, Shahinian H, Maya MM, Yong W, Heaney AP. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006; 7(6):518–520.PubMedCrossRefGoogle Scholar
  29. 29.
    Fadul CE, Kominsky AL, Meyer LP et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 2006; 105(4):621–626.PubMedCrossRefGoogle Scholar
  30. 30.
    Brown RL, Muzzafar T, Wollman R, Weiss RE. A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol 2006; 154(5):639–643.PubMedCrossRefGoogle Scholar
  31. 31.
    Guastamacchia E, Triggiani V, Tafaro E et al. Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report. Minerva Endocrinol 2007; 32(3):231–236.PubMedGoogle Scholar
  32. 32.
    Guzel A, Tatli M, Senturk S, Guzel E, Cayli SR, Sav A. Pituitary carcinoma presenting with multiple metastases: case report. J Child Neurol 2008; 23(12):1467–1471.PubMedCrossRefGoogle Scholar
  33. 33.
    Pinchot SN, Sippel R, Chen H. ACTH-producing carcinoma of the pituitary with refractory Cushing’s Disease and hepatic metastases: a case report and review of the literature. World J Surg Oncol 2009; 7:39.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Roncaroli F, Scheithauer BW, Horvath E et al. Silent Subtype 3 Carcinoma of the Pituitary: A Case Report. Neuropathol Appl Neurobiol 2009.Google Scholar
  35. 35.
    Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 2009; 161(4):631–637.PubMedCrossRefGoogle Scholar
  36. 36.
    Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010; 95(10):4592–4599.PubMedCrossRefGoogle Scholar
  37. 37.
    Vieira NL, Chimelli L, Pereira PJ et al. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr Pract 2013; 19(6):e145-e149.CrossRefGoogle Scholar
  38. 38.
    Bengtsson D, Joost P, Aravidis C, et al. Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort. J Clin Endocrinol Metab 2017; 102(11):3928–3932.PubMedCrossRefGoogle Scholar
  39. 39.
    Tufton N, Roncaroli F, Hadjidemetriou I, et al. Pituitary Carcinoma in a Patient with an SDHB Mutation. Endocr Pathol 2017; 28(4):320–325.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Rotman LE, Vaughan TB, Hackney JR, Riley KO. Long-term survival following transformation of an adrenocorticotropic hormone secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma: Case report. World Neurosurg 2018.Google Scholar
  41. 41.
    Lin AL, Jonsson P, Tabar V, et al. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. J Clin Endocrinol Metab 2018; 103(10):3925–3930.PubMedCrossRefGoogle Scholar
  42. 42.
    Yoo F, Kuan EC, Heaney AP, Bergsneider M, Wang MB. Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary 2018; 21(3):290–301.PubMedCrossRefGoogle Scholar
  43. 43.
    McCormack A, Dekkers OM, Petersenn S, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 2018; 178(3):265–276.PubMedCrossRefGoogle Scholar
  44. 44.
    Lenders N, McCormack A. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary 2018; 21(2):217–229.PubMedCrossRefGoogle Scholar
  45. 45.
    Guo F, Wang G, Wang F, Xu D, Liu X. Identification of Novel Genes Involved in the Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature Review. Front Oncol 2018; 8:510.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018; 31(6):900–909.PubMedCrossRefGoogle Scholar
  47. 47.
    Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D. H-ras mutations in human pituitary carcinoma metastases. J Clin Endocrinol Metab 1994; 78:842–846.PubMedGoogle Scholar
  48. 48.
    Cai WY, Alexander JM, Hedley-Whyte ET, et al. Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab 1994; 78:89–93.PubMedGoogle Scholar
  49. 49.
    Tanizaki Y, Jin L, Scheithauer BW, Kovacs K, Roncaroli F, Lloyd RV. P53 gene mutations in pituitary carcinomas. Endocr Pathol 2007; 18(4):217–222.PubMedCrossRefGoogle Scholar
  50. 50.
    Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003; 63(9):2251–2255.PubMedGoogle Scholar
  51. 51.
    Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER, Jr. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996; 38:765–771.PubMedCrossRefGoogle Scholar
  52. 52.
    Thapar K, Kovacs K, Scheithauer BW, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 1996; 38:99–107.PubMedCrossRefGoogle Scholar
  53. 53.
    Yang Z, Zhang T, Gao H. Genetic aspects of pituitary carcinoma: A systematic review. Medicine (Baltimore) 2016; 95(47):e5268.CrossRefGoogle Scholar
  54. 54.
    Monsalves E, Juraschka K, Tateno T, et al. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. Endocr Relat Cancer 2014; 21(4):R331-R344.PubMedCrossRefGoogle Scholar
  55. 55.
    Francois RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. J Natl Cancer Inst 2015; 107(8), djv123.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6):514–523.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Donovan LE, Arnal AV, Wang SH, Odia Y. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. CNS Oncol 2016; 5(4):203–209.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Leibowitz-Amit R, Mete O, Asa SL, Ezzat S, Joshua AM. Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. Endocr Pract 2014; 20(8):e145-e150.PubMedCrossRefGoogle Scholar
  59. 59.
    Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6):501–513.PubMedCrossRefGoogle Scholar
  60. 60.
    Joshua AM, Ezzat S, Asa SL, et al. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 2009; 94(1):5–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Raverot G, Castinetti F, Jouanneau E, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012; 76(6):769–775.CrossRefGoogle Scholar
  62. 62.
    Hirohata T, Asano K, Ogawa Y, et al. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 2013; 98(3):1130–1136.PubMedCrossRefGoogle Scholar
  63. 63.
    Royce ME, Hoff PM, Pazdur R. Novel oral chemotherapy agents. Curr Oncol Rep 2000; 2(1):31–37.PubMedCrossRefGoogle Scholar
  64. 64.
    Owen DH, Alexander AJ, Konda B, et al. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget 2017; 8(61):104046–104056.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL. Temozolomide (Temodar(R)) and capecitabine (Xeloda(R)) treatment of an aggressive corticotroph pituitary tumor. Pituitary 2011; 14(4):418–424.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Zacharia BE, Gulati AP, Bruce JN, et al. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 2014; 74(4):E447-E455.PubMedCrossRefGoogle Scholar
  67. 67.
    Opalinska M, Hubalewska-Dydejczyk A, Sowa-Staszczak A. Radiolabeled peptides: current and new perspectives. Q J Nucl Med Mol Imaging 2017; 61(2):153–167.PubMedGoogle Scholar
  68. 68.
    Fani M, Nicolas GP, Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. J Nucl Med 2017; 58(Suppl 2):61S–66S.PubMedCrossRefGoogle Scholar
  69. 69.
    Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary 2014; 17(3):227–231.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Omalkhaire M. Alshaikh
    • 1
    • 2
  • Sylvia L. Asa
    • 3
    • 4
  • Ozgur Mete
    • 3
    • 4
  • Shereen Ezzat
    • 1
    • 5
    Email author
  1. 1.Department of Medicine, Princess Margaret Cancer CentreUniversity Health Network and University of TorontoTorontoCanada
  2. 2.Department of MedicineAl Imam Mohammad Ibn Saud Islamic UniversityRiyadhSaudi Arabia
  3. 3.Department of PathologyUniversity Health NetworkTorontoCanada
  4. 4.Department of Laboratory Medicine and PathobiologyUniversity of TorontoTorontoCanada
  5. 5.Princess Margaret Cancer CentreUniversity Health NetworkTorontoCanada

Personalised recommendations

Cite article

Buy options